PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 44.8% in January

PolyPid Ltd. (NASDAQ:PYPD) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 27,918 shares, a growth of 44.8% from the January 15th total of 19,282 shares. Based on an average trading volume of 73,830 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the company’s stock are short sold. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 73,830 shares, the short-interest ratio is currently 0.4 days.

PolyPid Stock Down 3.5%

NASDAQ PYPD opened at $4.43 on Friday. The firm has a market cap of $70.42 million, a P/E ratio of -1.96 and a beta of 1.52. PolyPid has a 52-week low of $2.30 and a 52-week high of $5.12. The business’s 50-day moving average price is $4.37 and its 200 day moving average price is $3.81.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). As a group, analysts anticipate that PolyPid will post -1.79 earnings per share for the current year.

Institutional Trading of PolyPid

Several hedge funds and other institutional investors have recently made changes to their positions in PYPD. Lumbard & Kellner LLC acquired a new stake in PolyPid in the second quarter valued at $135,000. AIGH Capital Management LLC boosted its position in shares of PolyPid by 27.0% in the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after buying an additional 253,727 shares in the last quarter. Jane Street Group LLC acquired a new stake in PolyPid in the 4th quarter valued at about $66,000. HighTower Advisors LLC acquired a new stake in PolyPid in the 4th quarter valued at about $44,000. Finally, BNP Paribas Financial Markets increased its holdings in PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after acquiring an additional 3,500 shares in the last quarter. Hedge funds and other institutional investors own 26.47% of the company’s stock.

More PolyPid News

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $13 price target and models significant long‑term upside (FY2028 and FY2030 estimates were raised to positive territory), which supports a bullish narrative for PYPD’s eventual commercial prospects.
• Positive Sentiment: Management’s Q4 earnings call was described as upbeat and flagged a potentially material 2026 catalyst that investors may view as a near‑term growth trigger. PolyPid Earnings Call Flags Big 2026 Catalyst
• Neutral Sentiment: Full Q4 2025 earnings call transcript and highlight coverage are available for investors who want details on pipeline timing, trial milestones and cash guidance; these provide context but may not move the stock until the 2026 catalyst is clarified. Q4 2025 Earnings Call Highlights Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright materially lowered FY2026 EPS estimates (now forecasting a larger loss: -$1.69 vs prior -$1.46) and trimmed FY2029 slightly, signaling worse near‑term profitability than previously expected — a negative for short‑term sentiment.
• Negative Sentiment: PolyPid missed Q4 EPS expectations (reported -$0.41 vs consensus -$0.34), underscoring current cash‑burn/loss trends that weigh on the share price until clinical or commercial catalysts materialize. Earnings Call Transcript

Wall Street Analysts Forecast Growth

PYPD has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. Citigroup reissued a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of PolyPid in a research report on Wednesday. Finally, Roth Mkm reduced their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.